Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | F10 | P00742 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.31 |
| ▸ | TACR1 | P25103 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4283864 | 0.84 | F10 (0.33) | CYP2C19ALDH1A1F10PIK3CDTACR1 | |
| SCHEMBL29865291 | 0.82 | F10 (0.38) | KMT2AF10PIK3CDTACR1 | |
| SCHEMBL15972321 | 0.79 | DGAT1 (0.38) | CYP2C19ALDH1A1KMT2AF10L3MBTL1 | |
| SCHEMBL4292957 | 0.79 | F10 (0.35) | CYP2C19ALDH1A1F10PIK3CDTACR1 | |
| SCHEMBL474942 | 0.79 | CYP2C19 (0.46) | CYP2C19ALDH1A1PARP1KMT2ALMNA | |
| SCHEMBL7886958 | 0.78 | MEN1 (0.39) | CYP2C19ALDH1A1KMT2AF10L3MBTL1 | |
| SCHEMBL3152070 | 0.77 | CYP2C19 (0.41) | CYP2C19ALDH1A1PARP1KMT2AF10 | |
| SCHEMBL4282289 | 0.76 | F10 (0.35) | F10PIK3CDTACR1 | |
| SCHEMBL4475218 | 0.76 | F10 (0.35) | F10PIK3CD | |
| SCHEMBL1976258 | 0.75 | F10 (0.35) | ALDH1A1PARP1KMT2AF10PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| EP-1730148-A4 | AMINOBENZOXAZOLES AS THERAPEUTIC AGENTS | ABBOTT LAB (US) | 2009-08-19 | — | — | EP | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| WO-2008139941-A1 | SUBSTITUTED IMIDAZOLE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-20 | — | — | WO | disclosed |
| EP-1730148-A2 | AMINOBENZOXAZOLES AS THERAPEUTIC AGENTS | Abbott Laboratories (US) | 2006-12-13 | — | — | EP | disclosed |
| US-20060025383-A1 | Aminobenzoxazoles as therapeutic agents | ABBOTT LABORATORIES | 2006-02-02 | — | — | US | disclosed |
| WO-2005074603-A2 | AMINOBENZOXAZOLES AS THERAPEUTIC AGENTS | ABBOTT LABORATORIES (US) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025383-A1 | Aminobenzoxazoles as therapeutic agents | ABL1, MAP3K19, MAP3K20 | CYP2C19 351/4885ALDH1A1 1952/4885PARP1 1618/4885 |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | CYP2C19 19/4885ALDH1A1 388/4885PARP1 3523/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | CYP2C19 19/4885ALDH1A1 388/4885PARP1 3523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.